AbbVie has agreed to pay up to $2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, in an early-stage push on next-generation bispecific therapies.
Disco will receive $40 million upfront and up to $2.5 billion in milestone payments to develop AND-gated bispecific therapeutics for solid tumours. The approach is designed to recognise cancer cells only when two target proteins are present at the same time, which could reduce damage to healthy tissue. Disco chief executive Mark Manfredi said his company will run the research and discovery work, and AbbVie will hold the right to exclusively license selected programmes for further development once Disco completes specified research.
The deal is at a very early stage. Disco did not disclose how many programmes could be covered or when any could enter clinical development, and AbbVie’s license option applies only after the research is done. Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer and expects to select a development candidate in the second half of next year.
It is Disco’s second major pharma partnership of 2026, after a January licensing deal with Amgen worth up to $618 million. For AbbVie, it follows the $650 million upfront it paid RemeGen in January for rights outside China to a bispecific medicine targeting solid tumours, as bispecific antibodies draw increased interest across the large drugmakers, including Bristol Myers Squibb, Pfizer and Merck.